3,391 Shares in Becton, Dickinson and Company $BDX Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 3,391 shares of the medical instruments supplier’s stock, valued at approximately $513,000.

A number of other institutional investors have also recently bought and sold shares of the business. Auto Owners Insurance Co raised its stake in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. BlackRock Inc. bought a new position in Becton, Dickinson and Company during the second quarter valued at about $3,721,533,000. State Street Corp increased its holdings in Becton, Dickinson and Company by 0.8% during the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its holdings in Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 3.9%

Shares of Becton, Dickinson and Company stock opened at $187.82 on Thursday. The stock has a market capitalization of $51.75 billion, a P/E ratio of 56.57, a P/E/G ratio of 12.74 and a beta of 0.19. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.96. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock’s 50-day simple moving average is $159.86 and its 200 day simple moving average is $161.02.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business earned $3.68 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,779 shares of company stock valued at $1,974,669 in the last quarter. 0.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BDX shares. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Bank of America reduced their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.